These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 2193019)

  • 21. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation.
    Slavin S; Or R; Naparstek E; Cividalli G; Weshler Z; Weiss L; Mumcuoglu M; Engelhard D; Aker M; Pollack A
    Isr J Med Sci; 1986; 22(3-4):264-7. PubMed ID: 3528046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone marrow transplantation in miniature swine. III. Graft-versus-host disease and the effect of T cell depletion of marrow.
    Sakamoto K; Sachs DH; Shimada S; Popitz-Bergez FA; Pennington LR; Pescovitz MD; McDonough MA; MacVittie TJ; Katz SI; Gress RE
    Transplantation; 1988 May; 45(5):869-75. PubMed ID: 3285532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma.
    Przepiorka D; Giralt S; Huh YO; Andreeff M; Luna M; Reading C; Thomas M; Champlin RE
    Transplant Proc; 1992 Dec; 24(6):2906-7. PubMed ID: 1465994
    [No Abstract]   [Full Text] [Related]  

  • 25. Laboratory control in predicting clinical efficacy of T cell-depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis.
    Marciniak E; Romond EH; Thompson JS; Henslee PJ
    Bone Marrow Transplant; 1988 Nov; 3(6):589-98. PubMed ID: 3063328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
    Sykes M; Sharabi Y; Sachs DH
    Bone Marrow Transplant; 1988 Sep; 3(5):379-86. PubMed ID: 3056545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Graft-versus-leukemia activity after T-cell depletion using counterflow centrifugation.
    de Witte T; Preijers F; Schattenberg A
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():103-5. PubMed ID: 2202463
    [No Abstract]   [Full Text] [Related]  

  • 30. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
    Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
    Apperley JF; Jones L; Hale G; Waldmann H; Hows J; Rombos Y; Tsatalas C; Marcus RE; Goolden AW; Gordon-Smith EC
    Bone Marrow Transplant; 1986 May; 1(1):53-66. PubMed ID: 3332120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell depletion in allogeneic bone marrow transplantation for acute leukaemias.
    Aversa F; Terenzi A; Carotti A; Velardi A; Latini P; Gambelunghe C; Grignani F; Martelli MF
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():69-72. PubMed ID: 2697440
    [No Abstract]   [Full Text] [Related]  

  • 33. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results.
    Soiffer RJ; Ritz J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S7-10. PubMed ID: 8124262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
    Vossen J
    Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo depletion of T cells.
    Arnold R; Bunjes D; Wiesneth M; Hertenstein B; Theobald M; Heimpel H; Hale G; Waldmann H
    Bone Marrow Transplant; 1993; 12 Suppl 3():S11-2. PubMed ID: 8124250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
    Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-cell depletion and allogeneic bone marrow transplantation.
    O'Reilly RJ
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):20-6. PubMed ID: 1615341
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.